Screener
ArriVent BioPharma, Inc. AVBP Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchase of short-term and long-term investments | (64,383) | (9,817) |
| Sales and maturities of short-term and long-term investments | 67,965 | 46,638 |
| Net cash used in investing activities | 3,582 | 36,821 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs | 54,724 | 6,516 |
| Proceeds from the exercise of stock options | 149 | 293 |
| Payment of deferred financing costs | — | (50) |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s investing cash flow?
- ArriVent BioPharma, Inc. (AVBP) reported investing cash flow of $3.58M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s investing cash flow changed year-over-year?
- ArriVent BioPharma, Inc.'s investing cash flow decreased by 90.3% year-over-year, from $36.82M to $3.58M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about ArriVent BioPharma, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude